Not Applicable
Not Applicable
In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use. Some embodiments are directed to delivery systems, such as catheter systems of all types, which are utilized in the delivery of such devices.
Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices, collectively referred to hereinafter as stents, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. Stents may be implanted to prevent restenosis following angioplasty in the vascular system. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).
Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.
Within the vasculature, it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.
The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.
All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.
Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.
A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims.
At least one possible embodiment is directed to a stent comprising a tubular body having a sidewall with a plurality of openings therethrough. A portion of the sidewall has a plurality of rings which are concentric and interconnected, including a first ring and a second ring. Both rings have peaks and valleys. A first connector extending from a valley of the first ring to the valley of the second ring connects the rings.
At least one possible embodiment is directed to a stent wherein the first and second rings are connected by a plurality of connectors, the connectors extending from one valleys of the first ring to valleys of the second ring.
At least one possible embodiment is directed to a stent wherein each of the concentric rings has a plurality of peaks and valleys, each two adjacent concentric rings connected by at least one connector which extends from a valley of one of the two adjacent rings to a valley of the other of the two adjacent rings.
At least one possible embodiment is directed to a stent wherein each of the concentric rings has a plurality of peaks and valleys, each two adjacent concentric rings connected by a plurality of connectors which extend from valleys of one of the two adjacent rings to valleys of the other of the two adjacent rings.
At least one possible embodiment is directed to a stent in which the peaks and valleys of the concentric rings are out of phase with each other.
At least one possible embodiment is directed to a stent in which at least one connector is more rigid than at least one ring.
At least one possible embodiment is directed to a stent in which at least one ring is more rigid than at least one connector.
At least one possible embodiment is directed to a stent in which at least one connector and at least one concentric ring are constructed out of different materials.
At least one possible embodiment is directed to a stent in which the connectors are connected to every other valley of at least one ring.
At least one possible embodiment is directed to a bifurcated stent having a tubular sidewall, the sidewall including an expandable sidebranch portion, the expandable sidebranch portion having a plurality of rings which are concentric and interconnected, including a first ring and a second ring. Both rings have peaks and valleys. A first connector extending from a valley of the first ring to the valley of the second ring connects the rings.
At least one possible embodiment is directed to a bifurcated stent in which the first and second rings are connected by a plurality of connectors, the connectors extending from one valleys of the first ring to valleys of the second ring.
At least one possible embodiment is directed to a bifurcated stent in which the first ring defines the outermost end of the expandable sidebranch portion.
At least one possible embodiment is directed to a bifurcated stent in which the peaks and valleys of the concentric rings are out of phase with each other.
At least one possible embodiment is directed to a bifurcated stent in which at least one connector is more rigid than at least one ring.
At least one possible embodiment is directed to a bifurcated stent in which at least one ring is more rigid than at least one connector.
At least one possible embodiment is directed to a bifurcated stent in which at least one connector and at least one concentric ring are constructed out of different materials.
At least one possible embodiment is directed to a bifurcated stent in which the connectors are connected to every other valley of at least one ring.
At least one possible embodiment is directed to a bifurcated stent being expandable from an unexpanded state to an expanded state, wherein in the unexpanded state the stent has a diameter less than that of the diameter in the expanded state. The bifurcated stent comprises: a substantially tubular primary body defining a primary circumferential plane, a primary outer surface, a primary lumen and having a primary longitudinal axis extending therethrough and has a side opening and a side branch assembly engaged to the primary body opposite the side opening. The side branch assembly comprises at least two ring members. In the unexpanded state the at least two ring members are positioned substantially within the primary circumferential plane. In the expanded state at least one ring member is positioned external to the first circumferential plane and the at least two ring members define a secondary circumferential plane, a secondary lumen, and having a secondary longitudinal axis extending therethrough. The secondary lumen is in fluid communication with the primary lumen and the secondary longitudinal axis forms an oblique angle with the primary longitudinal axis. The ring members are interconnected by connectors and comprising a plurality of peaks and valleys, at least one of the connectors connecting the valley of one ring member to the valley of another ring member.
At least one possible embodiment is directed to a bifurcated stent in which one half of all the valleys of at least one ring members are connected to one half of the ring members of at least one other ring member.
These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof.
However, for further understanding of the invention, its advantages and objectives obtained by its use, reference can be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described embodiments of the invention.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.
For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.
Depicted in the figures are various aspects of the invention. Elements depicted in one figure may be combined with, and/or substituted for, elements depicted in another figure as desired.
Referring now to
First stent body 10 can be constructed from any suitable biocompatible material including but not limited to polymers, stainless steel, platinum, gold, cobalt, chromium, niobium etc. It can also be constructed out of one or more combinations and/or alloys of these materials.
An improved side branch assembly 30 is connected to first stent body 10 adjacent to the side opening 18. As illustrated in
The side branch assembly 30 of
Referring now to
For purposes of this application, the term “in phase” means the rings 33 are generally concentric and project towards and away from the center point 31 at relatively similar rotational positions along their perimeters. For example, peaks 50 of one ring 33 are aligned with peaks 50 of another ring 33 in a sidebranch radial direction In contrast, “out of phase” means the rings 33 are not in similar rotational positions. When rings are in phase, a connector 67 oriented along a vector generally directed towards the center point 31 is typically a peak-peak or valley-valley connection. Conversely, a connector 37 see
Referring now to
Although the figure shows a single side branch opening and a singe side branch assembly, there can be multiple side branch openings and side branch assemblies.
The sizes of the side branches can vary as well having larger, smaller or the same area, end-on-end length, or circumference in the extended or unextended states. Multiple side branch openings can be positioned anywhere along the length of the first stent body 1 and can be coaxially positioned relative to one another.
In embodiments wherein the side branch assembly 30 is configured to be self expanding, the stent 1 can be designed such that first body stent struts 5 can partially cover and restrain the side branch assembly 30 in the unexpanded state. In such an embodiment, as the first stent body 10 expands (whether through balloon expansion or by self expansion) its movement will move the covering struts 5 from the side branch assembly 30, allowing the side branch assembly to self-expand. In the case of a balloon expandable side branch assembly 30, the stent 1 can also be designed so that the unexpanded first stent struts 5 can at least partially cover the side branch assembly 30 and can be moved away as the first stent body 10 expands. As mentioned before, this inventive concept is not limited to stents comprising struts and can be accomplished with any stent structure in which in the unexpanded state the stent has a structural component adjacent to the structural components of the side branch assembly and in the expanded state the structural components are moved away from the side branch assembly.
One way to vary the degree of structural strength or flexibility that the expanded side branch assembly 30 will have is by constructing various parts of the side branch assembly 30 out of materials with different properties. For example, the connectors 39, connectors 37, and rings 33 can each be constructed out of different materials with differing structural strength or flexibility. In addition, each ring 33, each connector 37, or each connector 39, can be made out of similarly different materials.
The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, niobium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy and nickel-titanium alloys, for example, Nitinol.
The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon or after being heated to a transition temperature and having any restraints removed therefrom.
The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.
In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.
In some embodiments the at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto.
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.
Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.
This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.
Number | Name | Date | Kind |
---|---|---|---|
1596754 | Moschelle | Aug 1926 | A |
1861769 | Wappler | Jun 1932 | A |
2845959 | Sidebotham | Aug 1958 | A |
3872893 | Roberts | Mar 1975 | A |
4309994 | Grunwald | Jan 1982 | A |
4410476 | Redding et al. | Oct 1983 | A |
4413989 | Schjeldahl et al. | Nov 1983 | A |
4421810 | Rasmussen | Dec 1983 | A |
4454887 | Kruger | Jun 1984 | A |
4552554 | Gould et al. | Nov 1985 | A |
4681570 | Dalton | Jul 1987 | A |
4689174 | Lupke | Aug 1987 | A |
4730616 | Frisbie et al. | Mar 1988 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4896670 | Crittenden | Jan 1990 | A |
4900314 | Quackenbush | Feb 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4957508 | Kaneko et al. | Sep 1990 | A |
4983166 | Yamawaki | Jan 1991 | A |
4994071 | MacGregor | Feb 1991 | A |
5054501 | Chuttani et al. | Oct 1991 | A |
5122125 | Deuss | Jun 1992 | A |
5147317 | Shank et al. | Sep 1992 | A |
5156620 | Pigott | Oct 1992 | A |
5217440 | Frassica | Jun 1993 | A |
5219355 | Parodi et al. | Jun 1993 | A |
5244619 | Burnham | Sep 1993 | A |
5320605 | Sahota | Jun 1994 | A |
5337733 | Bauerfeind et al. | Aug 1994 | A |
5342387 | Summers | Aug 1994 | A |
5350395 | Yock | Sep 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5404887 | Prather | Apr 1995 | A |
5417208 | Winkler | May 1995 | A |
5443497 | Venbrux | Aug 1995 | A |
5445624 | Jimenez | Aug 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5458605 | Klemm | Oct 1995 | A |
5476471 | Shifrin et al. | Dec 1995 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5489271 | Andersen | Feb 1996 | A |
5496292 | Burnham | Mar 1996 | A |
5575771 | Walinsky | Nov 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5599300 | Weaver et al. | Feb 1997 | A |
5607444 | Lam | Mar 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5669932 | Fishell et al. | Sep 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5693086 | Goicoechea et al. | Dec 1997 | A |
5695516 | Fischell et al. | Dec 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5707348 | Krogh | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755770 | Ravenscroft | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755772 | Evans et al. | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5776101 | Goy | Jul 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5851464 | Davila et al. | Dec 1998 | A |
5853419 | Imran | Dec 1998 | A |
5855600 | Alt | Jan 1999 | A |
5868777 | Lam | Feb 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5916263 | Goicoechea et al. | Jun 1999 | A |
5921995 | Kleshinski | Jul 1999 | A |
5938696 | Goicoechea et al. | Aug 1999 | A |
5961490 | Adams | Oct 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5968089 | Krajicek | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
5984955 | Wisselink | Nov 1999 | A |
5993481 | Marcade et al. | Nov 1999 | A |
6013054 | Jiun Yan | Jan 2000 | A |
6013091 | Ley et al. | Jan 2000 | A |
6016810 | Ravenscroft | Jan 2000 | A |
6017324 | Tu et al. | Jan 2000 | A |
6017363 | Jojeibane | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6039758 | Quiachon et al. | Mar 2000 | A |
6045557 | White et al. | Apr 2000 | A |
6048360 | Khosravi et al. | Apr 2000 | A |
6048361 | Von Oepen | Apr 2000 | A |
6051020 | Goicoechea et al. | Apr 2000 | A |
6056722 | Jayaraman | May 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6059824 | Taheri | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6071298 | Lashinski et al. | Jun 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6090133 | Richter et al. | Jul 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6099558 | White | Aug 2000 | A |
6099560 | Penn et al. | Aug 2000 | A |
6102938 | Evans et al. | Aug 2000 | A |
6113579 | Eidenschink et al. | Sep 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6117156 | Richter et al. | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6129754 | Kanesaka et al. | Oct 2000 | A |
6132459 | Piplani et al. | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6165213 | Goccoechea et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6197046 | Piplani et al. | Mar 2001 | B1 |
6197049 | Shaolian et al. | Mar 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6210380 | Mauch | Apr 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210431 | Power | Apr 2001 | B1 |
6210433 | Larre | Apr 2001 | B1 |
6217527 | Selmon et al. | Apr 2001 | B1 |
6221080 | Power | Apr 2001 | B1 |
6221090 | Wilson | Apr 2001 | B1 |
6221098 | Wilson et al. | Apr 2001 | B1 |
6231563 | White et al. | May 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6238430 | Klumb et al. | May 2001 | B1 |
6248122 | Klumb et al. | Jun 2001 | B1 |
6251133 | Richter et al. | Jun 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6258073 | Mauch | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6261273 | Ruiz | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264662 | Lauterjung | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6273909 | Kugler et al. | Aug 2001 | B1 |
6283991 | Cox et al. | Sep 2001 | B1 |
6287277 | Yan | Sep 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293968 | Taheri | Sep 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6302908 | Parodi | Oct 2001 | B1 |
6306164 | Kujawski | Oct 2001 | B1 |
6312461 | Unsworth et al. | Nov 2001 | B1 |
6319278 | Quinn et al. | Nov 2001 | B1 |
6322587 | Quiachon et al. | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6325822 | Chouinard et al. | Dec 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6334870 | Ehr | Jan 2002 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6355060 | Lenker et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6383213 | Wilson et al. | May 2002 | B2 |
6387120 | Wilson et al. | May 2002 | B2 |
6395018 | Castaneda | May 2002 | B1 |
6436104 | Hojeibane | Aug 2002 | B2 |
6436134 | Richter et al. | Aug 2002 | B2 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6537284 | Inoue | Mar 2003 | B1 |
6540779 | Richter et al. | Apr 2003 | B2 |
6579309 | Loos | Jun 2003 | B1 |
6579312 | Wilson et al. | Jun 2003 | B2 |
6582394 | Reiss | Jun 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6599315 | Wilson | Jul 2003 | B2 |
6599316 | Vardi et al. | Jul 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6689156 | Davidson et al. | Feb 2004 | B1 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695877 | Brucker et al. | Feb 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6749628 | Callol et al. | Jun 2004 | B1 |
6776793 | Brown et al. | Aug 2004 | B2 |
6811566 | Penn et al. | Nov 2004 | B1 |
6835203 | Vardi | Dec 2004 | B1 |
6858038 | Heuser | Feb 2005 | B2 |
6884258 | Vardi et al. | Apr 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6955687 | Richter et al. | Oct 2005 | B2 |
6955688 | Wilson et al. | Oct 2005 | B2 |
6962602 | Vardi et al. | Nov 2005 | B2 |
7018400 | Lashinski et al. | Mar 2006 | B2 |
7056323 | Mareiro et al. | Jun 2006 | B2 |
7060091 | Killion et al. | Jun 2006 | B2 |
7341598 | Davidson et al. | Mar 2008 | B2 |
20010002443 | Parodi | May 2001 | A1 |
20010002927 | Detampel | Jun 2001 | A1 |
20010002943 | Nagayama et al. | Jun 2001 | A1 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20010004705 | Killion et al. | Jun 2001 | A1 |
20010004706 | Hojeibane | Jun 2001 | A1 |
20010004707 | Dereume et al. | Jun 2001 | A1 |
20010004823 | Cronin et al. | Jun 2001 | A1 |
20010007954 | Shaolian et al. | Jul 2001 | A1 |
20010012927 | Mauch | Aug 2001 | A1 |
20010016766 | Vardi et al. | Aug 2001 | A1 |
20010016767 | Wilson et al. | Aug 2001 | A1 |
20010016768 | Wilson et al. | Aug 2001 | A1 |
20010020173 | Klumb et al. | Sep 2001 | A1 |
20010020184 | Dehdashtian et al. | Sep 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010027291 | Shanley | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010029396 | Wilson et al. | Oct 2001 | A1 |
20010037116 | Wilson et al. | Nov 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010039448 | Dibie | Nov 2001 | A1 |
20010047199 | Wijay | Nov 2001 | A1 |
20010049552 | Richter et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020013619 | Shanley | Jan 2002 | A1 |
20020022874 | Wilson | Feb 2002 | A1 |
20020026232 | Marotta et al. | Feb 2002 | A1 |
20020035392 | Wilson | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052648 | McGuckin, Jr. et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020111675 | Wilson | Aug 2002 | A1 |
20020123791 | Harrison | Sep 2002 | A1 |
20020156516 | Vardi et al. | Oct 2002 | A1 |
20020156517 | Perouse | Oct 2002 | A1 |
20020165604 | Shanley | Nov 2002 | A1 |
20020173835 | Bourang et al. | Nov 2002 | A1 |
20020173840 | Brucker et al. | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020193872 | Trout, III et al. | Dec 2002 | A1 |
20020193873 | Brucker | Dec 2002 | A1 |
20030009209 | Hojeibane | Jan 2003 | A1 |
20030028233 | Vardi et al. | Feb 2003 | A1 |
20030050688 | Fischell et al. | Mar 2003 | A1 |
20030055378 | Wang et al. | Mar 2003 | A1 |
20030055483 | Gumm | Mar 2003 | A1 |
20030074047 | Richter | Apr 2003 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030181923 | Vardi | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040044396 | Clerc et al. | Mar 2004 | A1 |
20040059406 | Cully et al. | Mar 2004 | A1 |
20040088007 | Eidenschink | May 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040133268 | Davidson et al. | Jul 2004 | A1 |
20040138732 | Suhr et al. | Jul 2004 | A1 |
20040138737 | Davidson et al. | Jul 2004 | A1 |
20040148006 | Davidson et al. | Jul 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040186560 | Alt | Sep 2004 | A1 |
20040225345 | Fischell et al. | Nov 2004 | A1 |
20040267352 | Davidson | Dec 2004 | A1 |
20050004656 | Das | Jan 2005 | A1 |
20050010278 | Vardi et al. | Jan 2005 | A1 |
20050015108 | Williams et al. | Jan 2005 | A1 |
20050015135 | Shanley | Jan 2005 | A1 |
20050060027 | Khenansho et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050102023 | Yadin et al. | May 2005 | A1 |
20050113909 | Shannon et al. | May 2005 | A1 |
20050119731 | Brucker et al. | Jun 2005 | A1 |
20050125051 | Eidenschink et al. | Jun 2005 | A1 |
20050125076 | Ginn | Jun 2005 | A1 |
20050131526 | Wong | Jun 2005 | A1 |
20050149161 | Eidenschink et al. | Jul 2005 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20050154444 | Quadri et al. | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050209673 | Shaked | Sep 2005 | A1 |
20050228483 | Kaplan | Oct 2005 | A1 |
20060036315 | Yadin et al. | Feb 2006 | A1 |
20060041303 | Israel | Feb 2006 | A1 |
20060079956 | Eigler et al. | Apr 2006 | A1 |
20060173528 | Feld et al. | Aug 2006 | A1 |
20070073376 | Krolik et al. | Mar 2007 | A1 |
20070208411 | Meyer et al. | Sep 2007 | A1 |
20070276464 | Valencia et al. | Nov 2007 | A1 |
20080065197 | Meyer et al. | Mar 2008 | A1 |
20080086200 | Macha | Apr 2008 | A1 |
Number | Date | Country |
---|---|---|
2220864 | Jul 1999 | CA |
9014845 | Feb 1991 | DE |
29701883 | Mar 1997 | DE |
29701758 | May 1997 | DE |
0479730 | Oct 1991 | EP |
0686379 | Dec 1995 | EP |
0751752 | Jan 1997 | EP |
0783873 | Jul 1997 | EP |
0804907 | Nov 1997 | EP |
0479557 | Jul 1998 | EP |
0876805 | Nov 1998 | EP |
0647148 | Dec 1998 | EP |
0880949 | Dec 1998 | EP |
0891751 | Jan 1999 | EP |
0895759 | Feb 1999 | EP |
0897700 | Feb 1999 | EP |
0904745 | Mar 1999 | EP |
0937442 | Aug 1999 | EP |
0347023 | Dec 1999 | EP |
1031328 | Aug 2000 | EP |
1031329 | Aug 2000 | EP |
1031330 | Aug 2000 | EP |
0883384 | Dec 2000 | EP |
0862392 | Aug 2001 | EP |
0808140 | Dec 2001 | EP |
0884028 | Feb 2002 | EP |
1190685 | Mar 2002 | EP |
0684022 | Feb 2004 | EP |
1157674 | Jul 2005 | EP |
1070513 | Jun 2006 | EP |
2678508 | Jul 1991 | FR |
2740346 | Oct 1995 | FR |
2756173 | Nov 1996 | FR |
2760351 | Mar 1997 | FR |
2337002 | May 1998 | GB |
8806026 | Aug 1988 | WO |
9219308 | Nov 1992 | WO |
9510442 | Apr 1995 | WO |
9521592 | Aug 1995 | WO |
9629955 | Oct 1996 | WO |
9634580 | Nov 1996 | WO |
9641592 | Dec 1996 | WO |
9707752 | Mar 1997 | WO |
9715346 | May 1997 | WO |
9716217 | May 1997 | WO |
9726936 | Jul 1997 | WO |
9741803 | Nov 1997 | WO |
9745073 | Dec 1997 | WO |
9746174 | Dec 1997 | WO |
9819628 | May 1998 | WO |
9836709 | Aug 1998 | WO |
9837833 | Sep 1998 | WO |
9847446 | Oct 1998 | WO |
9847447 | Oct 1998 | WO |
9848879 | Nov 1998 | WO |
9853759 | Dec 1998 | WO |
9903426 | Jan 1999 | WO |
9903462 | Jan 1999 | WO |
9904726 | Feb 1999 | WO |
9913808 | Mar 1999 | WO |
9915103 | Apr 1999 | WO |
9915108 | Apr 1999 | WO |
9915109 | Apr 1999 | WO |
9924104 | May 1999 | WO |
9934749 | Jul 1999 | WO |
9936002 | Jul 1999 | WO |
9936015 | Jul 1999 | WO |
9944539 | Sep 1999 | WO |
9956661 | Nov 1999 | WO |
9965419 | Dec 1999 | WO |
0007523 | Feb 2000 | WO |
0010485 | Mar 2000 | WO |
0010489 | Mar 2000 | WO |
0013613 | Mar 2000 | WO |
0016719 | Mar 2000 | WO |
0027307 | May 2000 | WO |
0027463 | May 2000 | WO |
0028922 | May 2000 | WO |
0032266 | Jun 2000 | WO |
0044307 | Aug 2000 | WO |
0044309 | Aug 2000 | WO |
0047134 | Aug 2000 | WO |
0048531 | Aug 2000 | WO |
0049951 | Aug 2000 | WO |
0051523 | Sep 2000 | WO |
0057813 | Oct 2000 | WO |
0071054 | Nov 2000 | WO |
0067673 | Nov 2000 | WO |
0071055 | Nov 2000 | WO |
0074595 | Dec 2000 | WO |
0121095 | Mar 2001 | WO |
0121109 | Mar 2001 | WO |
0121244 | May 2001 | WO |
0130433 | May 2001 | WO |
0135715 | May 2001 | WO |
0135863 | May 2001 | WO |
0139697 | Jun 2001 | WO |
0139699 | Jun 2001 | WO |
0141677 | Jun 2001 | WO |
0143665 | Jun 2001 | WO |
0143809 | Jun 2001 | WO |
0145594 | Jun 2001 | WO |
0145785 | Jun 2001 | WO |
0149342 | Jul 2001 | WO |
0154621 | Aug 2001 | WO |
0154622 | Aug 2001 | WO |
0158385 | Aug 2001 | WO |
0160284 | Aug 2001 | WO |
0170294 | Sep 2001 | WO |
0170299 | Sep 2001 | WO |
0174273 | Oct 2001 | WO |
0189409 | Nov 2001 | WO |
0200138 | Jan 2002 | WO |
02053066 | Jul 2002 | WO |
02068012 | Sep 2002 | WO |
03007842 | Jan 2003 | WO |
03055414 | Jul 2003 | WO |
03063924 | Aug 2003 | WO |
2004026174 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2005009295 | Feb 2005 | WO |
2005014077 | Feb 2005 | WO |
2006028925 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20070135903 A1 | Jun 2007 | US |